






LNot if, but when
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Sundt EditorialsSee related article on page 1430.
In this issue of the Journal, Kapadia and colleagues1 share
their early experience with percutaneous aortic valve re-
placement (PAVR) as part of the ‘‘REVIVAL’’ trial, a
moniker imaginatively derived from the proper title ‘‘Trans-
catheter EndoVascular Implantation of VALves.’’ The aim
of this report is to characterize those patients referred for
the trial and the course of their care. There is an understand-
able focus on the number of patients eligible for the technol-
ogy and the effectiveness of PAVR. The study, like others,
shows what many of us once thought was not possible: (1)
despite our protestations that we turn down few patients
for surgery and there will be no appropriate place for a tech-
nology with unproven durability against a therapy that is
tried and true, there are indeed patients turned down for
open surgery even at a center of excellence such as theirs,
and (2) a tissue valve mounted on an expandable stent can
indeed be successfully implanted percutaneously without re-
moving the calcified native valve, and with remarkably good
results. Furthermore, judging by the enthusiasm of the pub-
lic as well as clinical (not interventional) cardiologists, the
results seem to be ‘‘good enough.’’ Like it or not, the ques-
tion is no longer if, but when. Some would answer ‘‘soon.’’
But the intent of my query is slightly different.
We can always rely on Francis Robicsek to put these mat-
ters into perspective. In a recent editorial in the European
Journal of Cardiothoracic Surgery, he2 raised appropriate
questions about this technology. It is true that PAVR is
brought to us by many of the same cardiologists who pro-
moted a technology most would classify as ‘‘failed,’’
namely, balloon aortic valvuloplasty. It is also true that man-
ufacturers are depending on short-term profit that must
surely come from use of the devices regardless of their per-
formance vis-a`-vis traditional valves. However, as my col-
league David Holmes is quick to admonish me, the
practice of tomorrow is built on the imperfect practice of
the past.
The results of this study do indeed demonstrate that, in ex-
pert and committed hands, PAVR can be applied in high-risk
patients at acceptable risk and that the fate of patients with
From the Mayo Clinic and Mayo Foundation, Rochester, Minn.
Received for publication Jan 30, 2009; accepted for publication Feb 6, 2009.
Address for reprints: Thoralf M. Sundt, MD, Mayo Clinic and Mayo Foundation,
200 First St, SW, Rochester, MN 55905 (E-mail: johnson.barbara4@mayo.edu).
J Thorac Cardiovasc Surg 2009;137:1315-6
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2009.02.023The Journal of Thoracic and Cthe disease left untreated is dismal. The conversation among
surgeons then frequently turns to concern that the technol-
ogy will be applied in ever lower risk patients in whom
we, as surgeons, are convinced surgery is preferable. The ob-
servation in this study that a good number of such patients
referred for PAVR turn out to be candidates for open aortic
valve replacement (AVR) is offered as appeasement.
But let’s put down our defensiveness and consider these
technologies as complementary, not competitive. Surely
the place of each will migrate somewhat, but it is likely
that, for the foreseeable future, both will have a place. The
question then is, ‘‘When a surgical AVR and when a percuta-
neous one?’’
In this study, one in five patients underwent surgical
AVR; what does this study tell us about the number of
‘‘high-risk’’ patients who are in fact eligible for surgical
AVR and their selection criteria? If we focus on the results
of AVR among these patients, we see that, again in expert
and committed hands, the operative mortality rate was re-
markably low—zero—and late survival was significantly
superior to that of PAVR. True, the numbers are small, but
so is the number zero.
Equally important is late survival. Again ‘‘operability’’
appears to be an important predictor. Among those undergo-
ing PAVR, the mortality rate exceeded 20% at just 9
months. True, most were not cardiac deaths, but how
much has been accomplished if we simply shift the cause
of death? This dismal late survival of patients judged not
operative candidates has been observed among high-risk
patients undergoing stent-graft repair of abdominal3 or tho-
racic4 aortic aneurysm. Again, quantifiable predictors need
to be identified if we are to have informed discussions
with our patients. If they knew that a procedure was unlikely
to change their overall survival, would they undertake it
regardless of its ‘‘invasiveness?’’
I am not convinced that the survival differences ob-
served are necessarily due to the effectiveness of the pro-
cedure itself; I rather suspect that they reflect the ability
of excellent clinicians to assess operability beyond the pa-
rameters entered into our risk scores. It is the impact of
‘‘unmeasured covariates’’ that enter into ‘‘clinical judg-
ment.’’ Although the patients undergoing open AVR as
a group had somewhat lower EuroSCORE and Society of
Thoracic Surgery Risk Scores than the PAVR group, their
estimated operative risk still exceeded 10%. The question
is, how do we turn the ‘‘foot of the bed test’’ into quanti-
tative, transferable information? How are we to pick out
the 20% of patients who, despite the numbers, should un-
dergo the more invasive but likely more durable open pro-








Lover percutaneous coronary intervention and coronary ar-
tery bypass grafting.
The ultimate place of PAVR vis-a`-vis open AVR is un-
clear, as is the place of transapical valve implantation. Dr
Robicsek warns us not to repeat the mistakes of the past,
and I agree with him. We have a good product in AVR,
just as we have even today in coronary bypass grafting. Al-
though we need to ever improve it—making it less invasive
and reducing mortality and morbidity even further—at the
same time we should be proud of the results achieved and
advocate appropriately for its place in the armamentarium
together with other therapies. We must not quit the field,
but neither should we engage in battle. Instead, together,
we should direct our attention to developing means of deter-
mining which patients are best served with each therapy, just
as is now happening with the Syntax Trial and the develop-
ment of the Syntax score.5 To be partners in this, we must be
more than technicians. We need to bring a meaningful per-
spective on the entire disease process to the table, including
a sophisticated understanding of the indications for interven-
tion as well as the late results. We must be disease experts.
And we need to have a better answer to the question,1316 The Journal of Thoracic and Cardiovascular S‘‘Why did you accept this patient for surgery?’’ than ‘‘He
looked seaworthy to me.’’
For the truly inoperable patient, PAVR is a blessing. For
the operable patient, it is a curse. It is up to us as surgeons to
work with our colleagues to learn when.
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